Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.
PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
515
Participants
Timeline
Start Date
April 30, 2024
Primary Completion Date
December 30, 2027
Study Completion Date
December 30, 2028
Conditions
Advanced Malignant Solid Tumours
Interventions
DRUG
SCTB14
SCTB14,IV
All Listed Sponsors
lead
Sinocelltech Ltd.
INDUSTRY
NCT06304818 - Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours. | Biotech Hunter | Biotech Hunter